Efficacy and Safety of Gadopiclenol The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol.

The Impact of Seeing the Full Picture Bracco’s standpoint on sustainability - and environmental sustainability in particular - is that it is essential to look at the full picture.

Bracco announces the birth of Bracco Japan Ltd Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Ltd.  as of April 1, 2023.

AI and Radiology: mutual game changers At ECR 2023 in Vienna, we discussed what means to be Gamechangers in radiology and how this aligns with the Bracco motto “Unlocking the Invisible”.

Vuebox: Support Get access to user manuals, support videos, FAQ and the ultrasound systems supported by VueBox®.

Vuebox: Request a test Vuebox:  Request a test

Bracco è Marchio Storico di Interesse Nazionale L’azienda, nata nel 1927 e oggi leader globale nella diagnostica per immagini, entra a far parte dell’esclusivo gruppo di imprese storiche che rappresentano la punta di diamante del Made in Italy.

Our New Iodine Recollection Pilot and Re.Viva Re.Viva works to capture and redeploy used substances in the positive momentum of the circular economy: the Bracco Iodine Recollection Pilot 

Data Reinforcing Efficacy and Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions Published in Radiology

Diagnostic challenges of benign/incidental lesions at Liver MRI and CEUS It will address the topic of MR imaging of benign lesions.